Drug Profile
Research programme: nitric oxide-donors - NicOx/Re-Vana Therapeutics
Alternative Names: NCX-1660; NCX-667; Research programme: eye disorders therapeutics - NicOx/Re-Vana TherapeuticsLatest Information Update: 02 Jan 2019
Price :
$50
*
At a glance
- Originator NicOx
- Developer NicOx; Re-Vana Therapeutics
- Class Antiglaucomas; Eye disorder therapies; Nitroso compounds
- Mechanism of Action Nitric oxide donors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Glaucoma; Ocular hypertension
Most Recent Events
- 21 Dec 2018 Discontinued for Glaucoma in France (Ophthalmic)
- 21 Dec 2018 Discontinued for Ocular hypertension in France (Ophthalmic)
- 20 Oct 2017 Nicox and Re-Vana Therapeutics enter into a collaboration agreement to develop sustained release formulations of nitric oxide donating compounds for Glaucoma and Ocular hypertension